共 10 条
- [1] Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2244 - +Mok, Tony S.Cheng, YingZhou, XiangdongLee, Ki HyeongNakagawa, KazuhikoNiho, SeijiLee, MinLinke, RolfRosell, RafaelCorral, JesusMigliorino, Maria RitaPluzanski, AdamSbar, Eric I.Wang, TaoWhite, Jane LiangWu, Yi-Long
- [2] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) : 947 - 957Mok, Tony S.Wu, Yi-LongThongprasert, SumitraYang, Chih-HsinChu, Da-TongSaijo, NagahiroSunpaweravong, PatrapimHan, BaohuiMargono, BenjaminIchinose, YukitoNishiwaki, YutakaOhe, YuichiroYang, Jin-JiChewaskulyong, BusyamasJiang, HaiyiDuffield, Emma L.Watkins, Claire L.Armour, Alison A.Fukuoka, Masahiro
- [3] Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. LANCET ONCOLOGY, 2016, 17 (05) : 577 - 589Park, KeunchilTan, Eng-HuatO'Byrne, KenZhang, LiBoyer, MichaelMok, TonyHirsh, VeraYang, James Chih-HsinLee, Ki HyeongLu, ShunShi, YuankaiKim, Sang-WeLaskin, JanessaKim, Dong-WanArvis, Catherine DubosKolbeck, Arvis KarlLaurie, Scott A.Tsai, Chun-MingShahidi, MehdiKim, MiyoungMassey, DanZazulina, VictoriaPaz-Ares, Luis
- [4] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial[J]. ANNALS OF ONCOLOGY, 2017, 28 (02) : 270 - 277Paz-Ares, L.Tan, E. -H.O'Byrne, K.Zhang, L.Hirsh, V.Boyer, M.Yang, J. C. -H.Mok, T.Lee, K. H.Lu, S.Shi, Y.Lee, D. H.Laskin, J.Kim, D. -W.Laurie, S. A.Kolbeck, K.Fan, J.Dodd, N.Marten, A.Park, K.
- [5] Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers[J]. LUNG CANCER, 2015, 88 (01) : 108 - 111Rangachari, DeepaYamaguchi, NorihiroVanderLaan, Paul A.Folch, ErikMahadevan, AnandFloyd, Scott R.Uhlmann, Erik J.Wong, Eric T.Dahlberg, Suzanne E.Huberman, Mark S.Costa, Daniel B.
- [6] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. LANCET ONCOLOGY, 2012, 13 (03) : 239 - 246Rosell, RafaelCarcereny, EnricGervais, RadjVergnenegre, AlainMassuti, BartomeuFelip, EnriquetaPalmero, RamonGarcia-Gomez, RamonPallares, CintaMiguel Sanchez, JosePorta, RutCobo, ManuelGarrido, PilarLongo, FlaviaMoran, TeresaInsa, AmeliaDe Marinis, FilippoCorre, RomainBover, IsabelIlliano, AlfonsoDansin, Ericde Castro, JavierMilella, MicheleReguart, NoemiAltavilla, GiuseppeJimenez, UlpianoProvencio, MarianoAngel Moreno, MiguelTerrasa, JosefaMunoz-Langa, JoseValdivia, JavierIsla, DoloresDomine, ManuelMolinier, OlivierMazieres, JulienBaize, NathalieGarcia-Campelo, RosarioRobinet, GillesRodriguez-Abreu, DelvysLopez-Vivanco, GuillermoGebbia, VittorioFerrera-Delgado, LiobaBombaron, PierreBernabe, ReyesBearz, AlessandraArtal, AngelCortesi, EnricoRolfo, ChristianSanchez-Ronco, MariaDrozdowskyj, Ana
- [7] Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis[J]. LANCET ONCOLOGY, 2011, 12 (11) : 1004 - 1012Shaw, Alice T.Yeap, Beow Y.Solomon, Benjamin J.Riely, Gregory J.Gainor, JustinEngelman, Jeffrey A.Shapiro, Geoffrey I.Costa, Daniel B.Ou, Sai-Hong I.Butaney, MohitSalgia, RaviMaki, Robert G.Varella-Garcia, MarileilaDoebele, Robert C.Bang, Yung-JueKulig, KimarySelaru, PaulinaTang, YiyunWilner, Keith D.Kwak, Eunice L.Clark, Jeffrey W.Iafrate, A. JohnCamidge, D. Ross
- [8] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) : 113 - 125Soria, J. -C.Ohe, Y.Vansteenkiste, J.Reungwetwattana, T.Chewaskulyong, B.Lee, K. H.Dechaphunkul, A.Imamura, F.Nogami, N.Kurata, T.Okamoto, I.Zhou, C.Cho, B. C.Cheng, Y.Cho, E. K.Voon, P. J.Planchard, D.Su, W. -C.Gray, J. E.Lee, S. -M.Hodge, R.Marotti, M.Rukazenkov, Y.Ramalingam, S. S.Boyer, MichaelLee, CheeHughes, BrettO'Byrne, KennethBriggs, PeterMilward, MichaelJohn, ThomasDemedts, IngelVansteenkiste, JohanBustin, FrederiqueBarrios, Carlos HenriqueTimcheva, ConstantaButts, CharlesGoss, GlenwoodJuergens, RosalynLeighl, NatashaCheng, SusannaBurkes, RonaldZhou, CaicunZhang, HelongShu, YongqianCheng, YingZhou, QingLi, WeiFeng, GuoshengHe, Yong
- [9] Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial[J]. LANCET ONCOLOGY, 2017, 18 (11) : 1454 - 1466Wu, Yi-LongCheng, YingZhou, XiangdongLee, Ki HyeongNakagawa, KazuhikoNiho, SeijiTsuji, FumitoLinke, RolfRosell, RafaelCorral, JesusMigliorino, Maria RitaPluzanski, AdamSbar, Eric I.Wang, TaoWhite, Jane LiangNadanaciva, SashiSandin, RickardMok, Tony S.
- [10] Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers[J]. CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2240 - 2247Yu, Helena A.Arcila, Maria E.Rekhtman, NatashaSima, Camelia S.Zakowski, Maureen F.Pao, WilliamKris, Mark G.Miller, Vincent A.Ladanyi, MarcRiely, Gregory J.